Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
June 05 2023 - 4:15PM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company
focused on transforming the lives of patients suffering from fluid
overload, today announced that Mike McCormick has been appointed to
the company’s Board of Directors. Mr. McCormick’s vast experience
includes more than 25 years of service in the medical device
industry through varying leadership roles for several private and
publicly traded companies. Mr. McCormick will also serve as Lead
Independent Director and serve as a member of the Audit Committee
and as Chair of the Nominating and Corporate Governance Committee
of the Board.
“We are delighted to welcome Mike to Nuwellis’ Board of
Directors. His deep experience as an executive in the medical
technology field brings tremendous value to our leadership team,”
said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “As a
former CEO of a publicly traded medical device company, I am
confident that Mike’s knowledge of the space will help us further
enhance our mission of transforming the lives of people suffering
from fluid overload.”
From 2010 to 2023, Mr. McCormick served as the Chief Executive
officer of Osprey Medical, a publicly traded, commercial-stage
interventional cardiology company focused on technologies to reduce
contrast-induced acute kidney injury. Prior to Osprey Medical, from
2003 to 2008, Mr. McCormick served as the Chief Executive Officer
of Anulex Technologies, Inc., a private company focused on
developing proprietary technologies to support the healing of
spinal soft tissues. During his tenure, Anulex Technologies was
successfully sold to Boston Scientific. Prior to Anulex
Technologies, Mr. McCormick was President of Centerpulse
Spine-Tech, a publicly traded company that was sold to Zimmer in
2003. Earlier in his career, Mr. McCormick held various sales and
sales management positions with Boston Scientific and Baxter. Mr.
McCormick received his Bachelor of Business Administration,
Business Management degree from the University of Texas at
Austin.
Mr. McCormick is currently a member of the board of directors at
Osprey Medical, Inc., and Formae, Inc. He also previously served on
the board of directors at OrthoCor Medical, as a director for the
Cardio Renal Society of America and on the board of directors at
Anulex Technologies.
“I am looking forward to joining Nuwellis’ Board of Directors,
as I believe the Company has an outstanding opportunity to help
patients suffering from fluid overload through its unique Aquadex
ultrafiltration therapy,” said Mike McCormick. “Nuwellis has long
been at the forefront in the treatment of fluid overload for
patients resistant to diuretics, and I look forward to contributing
my expertise to the Board and leadership team as they embark on the
next phase of growth.”
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is
a medical technology company dedicated to transforming the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
commercializing the Aquadex SmartFlow® system for ultrafiltration
therapy. Nuwellis is headquartered in Minneapolis, Minnesota, with
a wholly owned subsidiary in Ireland. For more information visit
www.nuwellis.com or visit us on LinkedIn and Twitter.
About the Aquadex SmartFlow SystemThe Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible, and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
CONTACTS
Nuwellis, Inc.Investors:
Vivian CervantesGilmartin Group ir@nuwellis.com
Media: Annika
ParishHealth+Commerceannika@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024